Minneapolis-based Bio-Techne Corp. acquired B-MoGen Biotechnologies Inc. to strengthen its pipeline of cell and gene therapy offerings.
Terms of the deal were not disclosed, but Bio-Techne said it financed the acquisition with cash on hand.
B-MoGen Biotechnologies was founded in 2015 as a startup out of the University of Minnesota and has about 20 employees. The private company focuses on gene engineering, editing and delivery tools.
The transaction will help commercialize B-MoGen's technology using Bio-Techne's resources.
Bio-Techne is a life sciences company with products for cell and gene therapy applications.
Fredrikson & Byron PA is acting as Bio-Techne's legal counsel, while Dorsey & Whitney LLP is serving as legal counsel to B-MoGen.